<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177889</url>
  </required_header>
  <id_info>
    <org_study_id>GWJ-TCM-2017</org_study_id>
    <nct_id>NCT03177889</nct_id>
  </id_info>
  <brief_title>Lung Dispersing, Turbid Descending and Gut Clearing Decoction for Bronchiectasis</brief_title>
  <acronym>LUNG-CLEAR</acronym>
  <official_title>Efficacy and Safety of Lung Dispersing, Turbid Descending and Gut Clearing Decoction on Clinically Stable Bronchiectasis (LUNG-CLEAR): A Multicenter, Randomized, Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchiectasis is a chronic airway disease which confers significant healthcare burden, with
      limited therapeutic approaches. From the perspective of traditional Chinese medicine,
      congenital insufficiency of the lung, spleen and kidney, when coupled with external injury or
      mood impairment, may collectively contribute to bronchiectasis pathogenesis due to heat
      trapping in the phlems, congestion of wind evils and stagnation of blood. Symptomatic
      treatment may be effective and safe for ameliorating respiratory symptoms and hindering
      disease progression of bronchiectasis. Here, the investigators have explored the Lung
      Dispersing, Turbid Descending and Gut Clearing Decoction (LTGD) which targets at expelling
      the wind evil in patients with bronchiectasis. The investigators sought to conduct a
      multicenter, randomized cross-over trial which investigates the efficacy and safety of LTGD
      on clinically stable bronchiectasis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Bronchiectasis Health Questionnaire scores at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the frequency of bronchiectasis exacerbation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to the first bronchiectasis exacerbation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in forced expiratory volume in one second at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour sputum volume at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in sputum purulence score at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients isolated with Pseudomonas aeruginosa at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>changes in sputum hydrogen peroxide level at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>changes in sputum catalase activity at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>changes in sputum total antioxidant capacity at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>changes in resonant frequency at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>changes in airway resistance measured at 5 Hz at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>changes in Quality-of-life-bronchiectasis questionnaire score at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>changes in sputum microbiota composition at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in AX at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in sputum superoxide dismutase activity at month 6 compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bronchiectasis Adult</condition>
  <condition>Traditional Chinese Medicine</condition>
  <condition>Quality of Life</condition>
  <condition>Exacerbation</condition>
  <arm_group>
    <arm_group_label>Usual treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCM treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional Chinese Medicine plus oral mucolytics (described above);
Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Traditional Chinese Medicine (TCM)</intervention_name>
    <description>Traditional Chinese Medicine plus oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid];
Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g
Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g</description>
    <arm_group_label>Usual treatment</arm_group_label>
    <arm_group_label>TCM treatment</arm_group_label>
    <other_name>TCM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 18 and 75 years;

          -  remained clinically stable (respiratory symptoms and lung function parameters not
             exceeding normal daily variations) for 4 consecutive weeks;

          -  no acute upper respiratory tract infections within 4 weeks;

          -  1 or more BEs within the previous 2 years

        Exclusion Criteria:

          -  Other unstable concomitant systemic illnesses (i.e. coronary heart disease, recent
             cerebral stroke, severe uncontrolled hypertension, active gastric or duodenal ulcer,
             uncontrolled diabetes, malignancy, hepatic or renal dysfunction);

          -  Concomitant asthma, allergic bronchopulmonary aspergillosis, or active tuberculosis;

          -  Concomitant chronic obstructive pulmonary disease as the predominant diagnosis;

          -  Treatment with inhaled, oral or systemic antibiotics within 4 weeks;

          -  Type 2 respiratory failure needing oxygen therapy or non-invasive mechanical
             ventilation;

          -  Females during lactation or pregnancy;

          -  Poor understanding or failure to properly operate the instrument;

          -  Participation in other clinical trials within 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-jie Guan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei-jie Guan, Ph.D.</last_name>
    <phone>+86-13826042052</phone>
    <email>battery203@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi-min Zhang, M.D.</last_name>
    <phone>+86-18928868345</phone>
    <email>zhangzhimin51666@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Pasteur MC, Bilton D, Hill AT; British Thoracic Society Non-CF Bronchiectasis Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010 Jul;65(7):577. doi: 10.1136/thx.2010.142778.</citation>
    <PMID>20627912</PMID>
  </reference>
  <reference>
    <citation>Loukides S, Horvath I, Wodehouse T, Cole PJ, Barnes PJ. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med. 1998 Sep;158(3):991-4.</citation>
    <PMID>9731036</PMID>
  </reference>
  <reference>
    <citation>Horvath I, Loukides S, Wodehouse T, Kharitonov SA, Cole PJ, Barnes PJ. Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. Thorax. 1998 Oct;53(10):867-70.</citation>
    <PMID>10193374</PMID>
  </reference>
  <reference>
    <citation>Tsang KW, Chan K, Ho P, Zheng L, Ooi GC, Ho JC, Lam W. Sputum elastase in steady-state bronchiectasis. Chest. 2000 Feb;117(2):420-6.</citation>
    <PMID>10669685</PMID>
  </reference>
  <reference>
    <citation>Quittner AL, O'Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O'Riordan TG, Barker AF. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2015 Jan;70(1):12-20. doi: 10.1136/thoraxjnl-2014-205918. Epub 2014 Oct 16.</citation>
    <PMID>25323621</PMID>
  </reference>
  <reference>
    <citation>Spinou A, Siegert RJ, Guan WJ, Patel AS, Gosker HR, Lee KK, Elston C, Loebinger MR, Wilson R, Garrod R, Birring SS. The development and validation of the Bronchiectasis Health Questionnaire. Eur Respir J. 2017 May 11;49(5). pii: 1601532. doi: 10.1183/13993003.01532-2016. Print 2017 May.</citation>
    <PMID>28495688</PMID>
  </reference>
  <reference>
    <citation>Zheng J, Zhong N. Normative values of pulmonary function testing in Chinese adults. Chin Med J (Engl). 2002 Jan;115(1):50-4.</citation>
    <PMID>11930658</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, Lin ZM, Zheng JP, Chen RC, Zhong NS. Sputum bacteriology in steady-state bronchiectasis in Guangzhou, China. Int J Tuberc Lung Dis. 2015 May;19(5):610-9. doi: 10.5588/ijtld.14.0613.</citation>
    <PMID>25868032</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Gu YY, Liu GH, Li HM, Chen RC, Zhong NS. Sputum matrix metalloproteinase-8 and -9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: clinical correlates and prognostic implications. Respirology. 2015 Oct;20(7):1073-81. doi: 10.1111/resp.12582. Epub 2015 Jun 30.</citation>
    <PMID>26122009</PMID>
  </reference>
  <results_reference>
    <citation>Zhang ZM, Ren PH, Wu ZJ, Zhang DP, Xie WJ. Personalized alternative therapy of intractable bronchiectasis-induced hemoptysis in a patient: syndrome differentiation and treatment according to individual physique category. J Thorac Dis. 2013 Jun;5(3):E115-7. doi: 10.3978/j.issn.2072-1439.2013.06.26.</citation>
    <PMID>23825784</PMID>
  </results_reference>
  <results_reference>
    <citation>Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, Lin ZM, Zheng JP, Chen RC, Zhong NS. Impulse oscillometry in adults with bronchiectasis. Ann Am Thorac Soc. 2015 May;12(5):657-65. doi: 10.1513/AnnalsATS.201406-280OC.</citation>
    <PMID>25654540</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2017</study_first_submitted>
  <study_first_submitted_qc>June 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>Weijie Guan</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

